Navigation Links
AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation

IRVINE, Calif., Nov. 22, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced the recent presentation by Diana Shih, Ph.D., Associate Professor of Medicine, Division of Cardiology at the David Geffen School of Medicine at UCLA, at the 2011 American Heart Association (AHA) Scientific Sessions in Orlando, Florida.  Dr. Shih's presentation included information on research sponsored by the Company which demonstrated that dietary supplementation of AHRO-001 resulted in a 95% reduction in arterial plaque formation at the innominate artery when compared to the control group.

The study results also revealed significant reduction in plasma cholesterol and dietary cholesterol absorption in the test subjects that received HDCA. HDCA supplementation also improved HDL function as measured by cholesterol efflux assay. These factors indicate multiple methods of action for an anti-atherogenic effect, suggesting a clear potential for new anti-atherosclerotic therapy.

"We are extremely pleased with the results of the UCLA study and want to thank Dr. Shih for all of her efforts on this presentation," said Thomas W. Gardner, CEO of AtheroNova. "The data from this study confirms and enhances our initial research and understanding of the compounds. As a result, we are moving forward with the preparation of an Investigative New Drug (IND) application with the Food and Drug Administration (FDA) for our atherosclerotic plaque regression compounds, in addition to, preparations for entry into Phase I human trials during 2012."

"Presenting such positive data to an audience of industry peers at AHA validates the potential of AtheroNova's compounds," Gardner concluded. 

Dr. Shih's presentation can be viewed on the American Heart Association's website at

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis, obesity and lipomas.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the value of Dr. Nicholls' appointment to AtheroNova's scientific advisory board, and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AtheroNova Rodman & Renshaw Presentation Now Online at
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
4. SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts
5. Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference
6. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
7. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
8. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
9. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
10. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
11. QPS Expands Into Toxicology Services With Acquisition of the Preclinical Unit of DCB Taiwan
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association ... 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award ... work with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
Breaking Biology News(10 mins):